Theriva Tangible Book Value Per Share from 2010 to 2024

TOVX Stock  USD 1.28  0.02  1.59%   
Theriva Biologics Tangible Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Tangible Book Value Per Share will likely drop to 21.01 in 2024. During the period from 2010 to 2024, Theriva Biologics Tangible Book Value Per Share regression line of annual values had r-squared of  0.06 and arithmetic mean of  6.25. View All Fundamentals
 
Tangible Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
22.11490683
Current Value
21.01
Quarterly Volatility
148.97155469
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.17. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Tangible Book Value Per Share Growth Pattern

Below is the plot of the Tangible Book Value Per Share of Theriva Biologics over the last few years. It is Theriva Biologics' Tangible Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
Tangible Book Value Per Share10 Years Trend
Pretty Stable
   Tangible Book Value Per Share   
       Timeline  

Theriva Tangible Book Value Per Share Regression Statistics

Arithmetic Mean6.25
Geometric Mean30.62
Coefficient Of Variation2,383
Mean Deviation71.53
Median22.11
Standard Deviation148.97
Sample Variance22,193
Range641
R-Value0.24
Mean Square Error22,541
R-Squared0.06
Significance0.39
Slope7.94
Total Sum of Squares310,695

Theriva Tangible Book Value Per Share History

2024 21.01
2023 22.11
2022 48.75
2021 5.37
2020 2.77
2019 6.99
2018 42.45

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Tangible Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Tangible Book Value Per Share 22.11  21.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.